Abstract
Background
Vasculogenic mimicry (VM) is an enigmatic physiological feature that influences blood supply within glioblastoma (GBM) tumors for their sustained growth. Previous studies identify NFATC3, FOSL1 and HNRNPA2B1 as significant mediators of VEGFR2, a key player in vasculogenesis, and their molecular relationships may be crucial for VM in GBM.
Aims
The aim of this study was to understand how NFATC3, FOSL1 and HNRNPA2B1 collectively influence VM in GBM.
Methods
We have investigated the underlying gene regulatory mechanisms for VM in GBM cell lines U251 and U373 in vitro and in vivo. In vitro cell-based assays were performed to explore the role of NFATC3, FOSL1 and HNRNPA2B1 in GBM cell proliferation, VM and migration, in the context of RNA interference (RNAi)-mediated knockdown alongside corresponding controls. Western blotting and qRT-PCR assays were used to examine VEGFR2 expression levels. CO-IP was employed to detect protein–protein interactions, ChIP was used to detect DNA–protein complexes, and RIP was used to detect RNA–protein complexes. Histochemical staining was used to detect VM tube formation in vivo.
Results
Focusing on NFATC3, FOSL1 and HNRNPA2B1, we found each was significantly upregulated in GBM and positively correlated with VM-like cellular behaviors in U251 and U373 cell lines. Knockdown of NFATC3, FOSL1 or HNRNPA2B1 each resulted in decreased levels of VEGFR2, a key growth factor gene that drives VM, as well as the inhibition of proliferation, cell migration and extracorporeal VM activity. Chromatin immunoprecipitation (ChIP) studies and luciferase reporter gene assays revealed that NFATC3 binds to the promoter region of VEGFR2 to enhance VEGFR2 gene expression. Notably, FOSL1 interacts with NFATC3 as a co-factor to potentiate the DNA-binding capacity of NFATC3, resulting in enhanced VM-like cellular behaviors. Also, level of NFATC3 protein in cells was enhanced through HNRNPA2B1 binding of NFATC3 mRNA. Furthermore, RNAi-mediated silencing of NFATC3, FOSL1 and HNRNPA2B1 in GBM cells reduced their capacity for tumor formation and VM-like behaviors in vivo.
Conclusion
Taken together, our findings identify NFATC3 as an important mediator of GBM tumor growth through its molecular and epistatic interactions with HNRNPA2B1 and FOSL1 to influence VEGFR2 expression and VM-like cellular behaviors.
Graphical Abstract
1. NFATC3 binds to the promoter region of VEGFR2 to enhance VEGFR2 gene expression which leads to an increase in VM of GBM.
2. FOSL1 interacts with NFATC3 to further facilitate VEGFR2 gene expression and VM.
3. HNRNPA2B1 enhances NFATC3 mRNA stability to increase VEGFR2 expression and VM.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
Gliomas are one of the most common primary malignant brain tumors diagnosed in adults and arises as a consequence of uncontrolled growth of glial cells or their precursors. The World Health Organization (WHO) classifies gliomas into four grades based upon growth patterns and detected mutations to isocitrate dehydrogenase, among which glioblastoma (GBM) is recognized as the highest grade (IV) glioma (Lapointe et al. 2018; Louis et al. 2016). GBM is an invasive solid tumor, and the main treatment methods include surgery, radiotherapy, temozolomide chemotherapy (Lapointe, et al. 2018; Weller et al. 2017). In addition, GBM treatments with the anti-vascular drug bevacizumab also show promise, and patients prescribe with this treatment show reductions in peritumor edema and corticosteroid use, and a significant increase in progression-free survival, yet overall survival did not improve. The median survival time of GBM patients is less than two years, while the five-year survival rate is only 5% (Lofgren et al. 2022; Yang et al. 2022).
In GBM, tumors can form unique patterns of tube-like formations in which tumor cells replace the endothelium and form a structure that appears similar to blood vessels, a cellular phenomenon described as vasculogenic mimicry (VM). The cellular features of VM include the prominence of matrix protein-rich cells that do not express endothelial markers such as CD31 and CD34, while showing positive histochemical staining for periodic acid–Schiff (PAS) that detects the abundant carbohydrate stores (predominantly glycogen) in tumor cells, and the presence of blood components (Maniotis et al. 1999; ** vasculature. Cell. 2001;105(7):863–75. https://doi.org/10.1016/s0092-8674(01)00396-8 ." href="/article/10.1007/s10565-024-09890-5#ref-CR16" id="ref-link-section-d114376091e1914">2001). Our study shows that in GBM cells, an upregulation of NFATC3 likely leads to binding of the VEGFR2 promoter to transcriptionally activate VEGFR2 expression which, in turn, leads to an increase in VM tubes. Guided by the findings from previous studies and our current results, we speculate that there is a NFATC3-VEGFR2-NFATC3 regulatory loop that modulates VM formation in GBM. This is reminiscent of a postulated NFATC3-VEGFR2-NFATC3 signaling loop in breast cancer (Zhao et al. 2016). Furthermore, we verified that knockdown of NFATC3 inhibited the proliferation and migration capacities of GBM cells, which was consistent with previous findings (Urso et al. 2019).
FOSL1 belongs to the FOS family of transcription factors, and binds JUN to form the AP1 transcription factor complex, comprising a basic leucine zipper structure. This complex recognizes and bind DNA regulatory sequences known as TPA responsive elements (TRE) (Jiang et al. 2020), and FOSL1 can also dimerize with other transcription factors that are not AP1 members, but its function in those signaling contexts are less clear (Sobolev et al. 2022). We detected the binding of FOSL1 to NFATC3 in GBM and predicted possible binding sites for FOSL1 and NFATC3. However, in GBM cells that stably expression NFATC3 shRNA to suppress the expression of this gene, we found no evidence of binding by FOSL1 to the VEGFR2 promoter region. Furthermore, knockdown of FOSL1 in GBM cells led to reduced binding of NFATC3 to the VEGFR2 promoter. Furthermore, disruption to HNRNPA2B1 expression had no effect on FOSL1 mRNA levels. These lines of evidence indicate that FOSL1 and NFATC3 interact to transcriptionally co-regulate VEGFR2 expression in an NFATC3-dependent manner. This is consistent with the finding that NFAT interacts with the AP1 complex to promote transcription of another target, IL-13Ra2, in GBM cells (Wu et al. 2010).
HNRNPA2B1 is an RNA-binding protein that is prominent in cancer research. Elevated levels of HNRNPA2B1 are observed in gastric cancer (Hu et al. 2023), pancreatic cancer (Dai et al. 2017) and lung cancer (Yu et al. 2018), and this gene influences the proliferation and migration of cancer cells. Our knockdown studies with GMB cells also found that HNRNPA2B1 was necessary for the proliferation and migration of GBM cells. We detected that HNRNPA2B1 enriched NFATC3 mRNA rather than VEGFR2 mRNA, and knockdown of HNRNPA2B1 reduced the half-life of NFATC3 mRNA and not VEGFR2 mRNA. When we suppressed NFATC3 and VEGFR2 in stable transfected GBM cell lines using shRNAs, we found that this curtailed VM-like behaviors in GBM. These results suggest that HNRNPA2B1 influences VM-like behaviors in GBM by stabilizing NFATC3 mRNA. This is consistent with a previous study that reported that HNRNPA2B1 increases the expression of the VM marker MMP2 in GBM (Deng et al. 2016), and suggests that HNRNPA2B1 promotes VM formation in GBM through multiple pathways.
Through our in vivo experiments, we demonstrated that knockdown of NFATC3, FOSL1, and HNRNPA2B1 inhibited VM-like behaviors and resulted in a significant decrease in xenografted GBM tumors, both their sizes and volumes. Within GBM cell lines U251 and U373, we found that the regulation of VEGFR2 by HNRNPA2B1 and FOSL1 required the participation of NFATC3, such that NFATC3 was downstream of the signaling pathway. Our results are reminiscent of a study which reported that mice lacking NFATC3 showed decreased colorectal tumor numbers and reduced tumor sizes (Lin, et al. 2020). Drugs that inhibit NFAT, such as tacrolimus and cyclosporin A (CSA) that inhibit phosphatases, have demonstrated anticancer activity that is accompanied by immunosuppressive side effects (Durnian et al. 2007; Azzi et al. 2013). Considering the presence of the blood–brain barrier and phosphatase inhibition of many types of NFAT, the search for small molecule drugs that are more specific to NFATC3 could be an appropriate future direction for novel GBM treatments. This is one direction of our future research.
Conclusion
We find that HNPNPA2B1, NFATC3 and FOSL1 are highly expressed in GBM cells and are associated with their cellular behaviors including cell proliferation, migration and the formation of tube-like structures reminiscent of VM. We find that NFATC3 promotes VM formation and transcriptionally upregulates VEGFR2 transcription. FOSL1 interacts with NFATC3 to further facilitate VEGFR2 gene expression and VM. Furthermore, the half-life of NFATC3 mRNA is prolonged by HNRNPA2B1, and NFATC3 expression is increased, ultimately leading to enhanced VM. Taken altogether, our findings suggest that targeting NFATC3 and its interacting partners could represent a viable strategy to develop novel treatments for GBM with VM features.
Data availability
The datasets and materials generated and/or analyzed during the current study are available from the corresponding author on reasonable request.
Abbreviations
- VM:
-
Vasculogenic mimicry
- GBM:
-
Glioblastoma
- ChIP:
-
Chromatin immunoprecipitation
- WHO:
-
The World Health Organization
- PAS:
-
Periodic acid–Schiff
- NFAT:
-
Nuclear factor of activated T cells
- AP1:
-
Activator protein 1
- NHD:
-
NFAT homology domain
- RHD:
-
Rel-homology domain
- CDS:
-
Calcineurin-docking site
- HA:
-
Normal human astrocytes
- RIP:
-
RNA immunoprecipitation
- CO-IP:
-
Co-Immunoprecipitation
- CSA:
-
Cyclosporin A
References
Alghanem AF, Wilkinson EL, Emmett MS, Aljasir MA, Holmes K, Rothermel BA, Simms VA, Heath VL, Cross MJ: RCAN1.4 regulates VEGFR-2 internalisation, cell polarity and migration in human microvascular endothelial cells. Angiogenesis. 2017;20(3):341–58. https://doi.org/10.1007/s10456-017-9542-0.
Angara K, Borin TF, Arbab AS. Vascular Mimicry: A Novel Neovascularization Mechanism Driving Anti-Angiogenic Therapy (AAT) Resistance in Glioblastoma. Transl Oncol. 2017;10(4):650–60. https://doi.org/10.1016/j.tranon.2017.04.007.
Armesilla AL, Lorenzo E. Gomez del Arco P, Martinez-Martinez S, Alfranca A, Redondo JM: Vascular endothelial growth factor activates nuclear factor of activated T cells in human endothelial cells: a role for tissue factor gene expression. Mol Cell Biol. 1999;19(3):2032–43. https://doi.org/10.1128/MCB.19.3.2032.
Azzi JR, Sayegh MH, Mallat SG. Calcineurin inhibitors: 40 years later, can’t live without. J Immunol. 2013;191(12):5785–91. https://doi.org/10.4049/jimmunol.1390055.
Batchelor TT, Duda DG, di Tomaso E, Ancukiewicz M, Plotkin SR, Gerstner E, Eichler AF, Drappatz J, Hochberg FH, Benner T, Louis DN, Cohen KS, Chea H, Exarhopoulos A, Loeffler JS, Moses MA, Ivy P, Sorensen AG, Wen PY, Jain RK. Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol. 2010;28(17):2817–23. https://doi.org/10.1200/JCO.2009.26.3988.
Bengsch B, Wherry EJ. The importance of cooperation: partnerless NFAT induces T cell exhaustion. Immunity. 2015;42(2):203–5. https://doi.org/10.1016/j.immuni.2015.01.023.
Buccarelli M, Castellani G, Ricci-Vitiani L: Glioblastoma-Specific Strategies of Vascularization: Implications in Anti-Angiogenic Therapy Resistance. J Pers Med. 2022;12(10). https://doi.org/10.3390/jpm12101625.
Chigurupati S, Venkataraman R, Barrera D, Naganathan A, Madan M, Paul L, Pattisapu JV, Kyriazis GA, Sugaya K, Bushnev S, Lathia JD, Rich JN, Chan SL. Receptor channel TRPC6 is a key mediator of Notch-driven glioblastoma growth and invasiveness. Cancer Res. 2010;70(1):418–27. https://doi.org/10.1158/0008-5472.CAN-09-2654.
Cui J, Liu X, Dong W, Liu Y, Ruan X, Zhang M, Wang P, Liu L, Xue Y. SNORD17-mediated KAT6B mRNA 2’-O-methylation regulates vasculogenic mimicry in glioblastoma cells. Cell Biol Toxicol. 2023. https://doi.org/10.1007/s10565-023-09805-w.
Dai S, Zhang J, Huang S, Lou B, Fang B, Ye T, Huang X, Chen B, Zhou M. HNRNPA2B1 regulates the epithelial-mesenchymal transition in pancreatic cancer cells through the ERK/snail signaling pathway. Cancer Cell Int. 2017;17:12. https://doi.org/10.1186/s12935-016-0368-4.
Deng J, Chen S, Wang F, Zhao H, **e Z, Xu Z, Zhang Q, Liang P, Zhai X, Cheng Y. Effects of hnRNP A2/B1 Knockdown on Inhibition of Glioblastoma Cell Invasion. Growth and Survival Mol Neurobiol. 2016;53(2):1132–44. https://doi.org/10.1007/s12035-014-9080-3.
Duncan MC. New directions for the clathrin adaptor AP-1 in cell biology and human disease. Curr Opin Cell Biol. 2022;76: 102079. https://doi.org/10.1016/j.ceb.2022.102079.
Durnian JM, Stewart RM, Tatham R, Batterbury M, Kaye SB. Cyclosporin-A associated malignancy. Clin Ophthalmol. 2007;1(4):421–30.
Ellert-Miklaszewska A, Szymczyk A, Poleszak K, Kaminska B: Delivery of the VIVIT Peptide to Human Glioma Cells to Interfere with Calcineurin-NFAT Signaling. Molecules. 2021;26(16). https://doi.org/10.3390/molecules26164785.
Goshima T, Habara M, Maeda K, Hanaki S, Kato Y, Shimada M. Calcineurin regulates cyclin D1 stability through dephosphorylation at T286. Sci Rep. 2019;9(1):12779. https://doi.org/10.1038/s41598-019-48976-7.
Graef IA, Chen F, Chen L, Kuo A, Crabtree GR. Signals transduced by Ca(2+)/calcineurin and NFATc3/c4 pattern the develo** vasculature. Cell. 2001;105(7):863–75. https://doi.org/10.1016/s0092-8674(01)00396-8.
Hu L, Liu S, Yao H, Hu Y, Wang Y, Jiang J, Li X, Fu F, Yin Q, Wang H. Identification of a novel heterogeneous nuclear ribonucleoprotein A2B1 (hnRNPA2B1) ligand that disrupts HnRNPA2B1/nucleic acid interactions to inhibit the MDMX-p53 axis in gastric cancer. Pharmacol Res. 2023;189: 106696. https://doi.org/10.1016/j.phrs.2023.106696.
Huang Y, Zhu C, Liu P, Ouyang F, Luo J, Lu C, Tang B, Yang X. L1CAM promotes vasculogenic mimicry formation by miR-143-3p-induced expression of hexokinase 2 in glioma. Mol Oncol. 2023;17(4):664–85. https://doi.org/10.1002/1878-0261.13384.
Huelga SC, Vu AQ, Arnold JD, Liang TY, Liu PP, Yan BY, Donohue JP, Shiue L, Hoon S, Brenner S, Ares M Jr, Yeo GW. Integrative genome-wide analysis reveals cooperative regulation of alternative splicing by hnRNP proteins. Cell Rep. 2012;1(2):167–78. https://doi.org/10.1016/j.celrep.2012.02.001.
Jain J, Burgeon E, Badalian TM, Hogan PG, Rao A. A similar DNA-binding motif in NFAT family proteins and the Rel homology region. J Biol Chem. 1995;270(8):4138–45.
Jiang X, **e H, Dou Y, Yuan J, Zeng D, **ao S. Expression and function of FRA1 protein in tumors. Mol Biol Rep. 2020;47(1):737–52. https://doi.org/10.1007/s11033-019-05123-9.
Kamoun WS, Ley CD, Farrar CT, Duyverman AM, Lahdenranta J, Lacorre DA, Batchelor TT, di Tomaso E, Duda DG, Munn LL, Fukumura D, Sorensen AG, Jain RK. Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice. J Clin Oncol. 2009;27(15):2542–52. https://doi.org/10.1200/JCO.2008.19.9356.
Kasim M, Benko E, Winkelmann A, Mrowka R, Staudacher JJ, Persson PB, Scholz H, Meier JC, Fahling M. Shutdown of achaete-scute homolog-1 expression by heterogeneous nuclear ribonucleoprotein (hnRNP)-A2/B1 in hypoxia. J Biol Chem. 2014;289(39):26973–88. https://doi.org/10.1074/jbc.M114.579391.
Lapointe S, Perry A, Butowski NA. Primary brain tumours in adults. Lancet. 2018;392(10145):432–46. https://doi.org/10.1016/S0140-6736(18)30990-5.
Li JH, Liu S, Zhou H, Qu LH, Yang JH: starBase v2.0: decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA interaction networks from large-scale CLIP-Seq data. Nucleic Acids Res 2014;42(Database issue):D92–7. https://doi.org/10.1093/nar/gkt1248.
Lin Y, Koumba MH, Qu S, Wang D, Lin L. Blocking NFATc3 ameliorates azoxymethane/dextran sulfate sodium induced colitis-associated colorectal cancer in mice via the inhibition of inflammatory responses and epithelial-mesenchymal transition. Cell Signal. 2020;74: 109707. https://doi.org/10.1016/j.cellsig.2020.109707.
Lin Z, Xu H, Yang R, Li Z, Zheng H, Zhang Z, Peng J, Zhang X, Qi S, Liu Y, Huang G. Effective treatment of a BRAF V600E-mutant epithelioid glioblastoma patient by vemurafenib: a case report. Anticancer Drugs. 2022;33(1):100–4. https://doi.org/10.1097/CAD.0000000000001130.
Liu Y, Shi SL. The roles of hnRNP A2/B1 in RNA biology and disease. Wiley Interdiscip Rev RNA. 2021;12(2): e1612. https://doi.org/10.1002/wrna.1612.
Liu XM, Zhang QP, Mu YG, Zhang XH, Sai K, Pang JC, Ng HK, Chen ZP. Clinical significance of vasculogenic mimicry in human gliomas. J Neurooncol. 2011;105(2):173–9. https://doi.org/10.1007/s11060-011-0578-5.
Lofgren D, Valachis A, Olivecrona M. Risk for morbidity and mortality after neurosurgery in older patients with high grade gliomas - a retrospective population based study. BMC Geriatr. 2022;22(1):805. https://doi.org/10.1186/s12877-022-03478-6.
Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016;131(6):803–20. https://doi.org/10.1007/s00401-016-1545-1.
Luo Q, Wang J, Zhao W, Peng Z, Liu X, Li B, Zhang H, Shan B, Zhang C, Duan C. Vasculogenic mimicry in carcinogenesis and clinical applications. J Hematol Oncol. 2020;13(1):19. https://doi.org/10.1186/s13045-020-00858-6.
Macian F. NFAT proteins: key regulators of T-cell development and function. Nat Rev Immunol. 2005;5(6):472–84. https://doi.org/10.1038/nri1632.
Maniotis AJ, Folberg R, Hess A, Seftor EA, Gardner LM, Pe’er J, Trent JM, Meltzer PS, Hendrix MJ. Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol. 1999;155(3):739–52. https://doi.org/10.1016/S0002-9440(10)65173-5.
Mao JM, Liu J, Guo G, Mao XG, Li CX. Glioblastoma vasculogenic mimicry: signaling pathways progression and potential anti-angiogenesis targets. Biomark Res. 2015;3:8. https://doi.org/10.1186/s40364-015-0034-3.
Ning H, Zhang L, Zhu B, Zhou X, Zhang T, Ma T. TARBP2-stablized SNHG7 regulates blood-brain barrier permeability by acting as a competing endogenous RNA to miR-17-5p/NFATC3 in Abeta-microenvironment. Cell Death Dis. 2022;13(5):457. https://doi.org/10.1038/s41419-022-04920-8.
Qin JJ, Nag S, Wang W, Zhou J, Zhang WD, Wang H, Zhang R. NFAT as cancer target: mission possible? Biochim Biophys Acta. 2014;1846(2):297–311. https://doi.org/10.1016/j.bbcan.2014.07.009.
Ray D, Kazan H, Cook KB, Weirauch MT, Najafabadi HS, Li X, Gueroussov S, Albu M, Zheng H, Yang A, Na H, Irimia M, Matzat LH, Dale RK, Smith SA, Yarosh CA, Kelly SM, Nabet B, Mecenas D, Li W, Laishram RS, Qiao M, Lipshitz HD, Piano F, Corbett AH, Carstens RP, Frey BJ, Anderson RA, Lynch KW, Penalva LO, Lei EP, Fraser AG, Blencowe BJ, Morris QD, Hughes TR. A compendium of RNA-binding motifs for decoding gene regulation. Nature. 2013;499(7457):172–7. https://doi.org/10.1038/nature12311.
Ryeom S, Baek KH, Rioth MJ, Lynch RC, Zaslavsky A, Birsner A, Yoon SS, McKeon F. Targeted deletion of the calcineurin inhibitor DSCR1 suppresses tumor growth. Cancer Cell. 2008;13(5):420–31. https://doi.org/10.1016/j.ccr.2008.02.018.
Serfling E, Barthelmas R, Pfeuffer I, Schenk B, Zarius S, Swoboda R, Mercurio F, Karin M. Ubiquitous and lymphocyte-specific factors are involved in the induction of the mouse interleukin 2 gene in T lymphocytes. EMBO J. 1989;8(2):465–73. https://doi.org/10.1002/j.1460-2075.1989.tb03399.x.
Sobolev VV, Khashukoeva AZ, Evina OE, Geppe NA, Chebysheva SN, Korsunskaya IM, Tchepourina E, Mezentsev A: Role of the Transcription Factor FOSL1 in Organ Development and Tumorigenesis. Int J Mol Sci. 2022;23(3). https://doi.org/10.3390/ijms23031521.
Tong Y, Zhang Z, Cheng Y, Yang J, Fan C, Zhang X, Yang J, Wang L, Guo D, Yan D. Hypoxia-induced NFATc3 deSUMOylation enhances pancreatic carcinoma progression. Cell Death Dis. 2022;13(4):413. https://doi.org/10.1038/s41419-022-04779-9.
Urso K, Fernandez A, Velasco P, Cotrina J, de Andres B, Sanchez-Gomez P, Hernandez-Lain A, Hortelano S, Redondo JM, Cano E. NFATc3 controls tumour growth by regulating proliferation and migration of human astroglioma cells. Sci Rep. 2019;9(1):9361. https://doi.org/10.1038/s41598-019-45731-w.
Weller M, van den Bent M, Tonn JC, Stupp R, Preusser M, Cohen-Jonathan-Moyal E, Henriksson R, Le Rhun E, Balana C, Chinot O, Bendszus M, Reijneveld JC, Dhermain F, French P, Marosi C, Watts C, Oberg I, Pilkington G, Baumert BG, Taphoorn MJB, Hegi M, Westphal M, Reifenberger G, Soffietti R, Wick W. European Association for Neuro-Oncology Task Force on G: European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. Lancet Oncol. 2017;18(6):e315–29. https://doi.org/10.1016/S1470-2045(17)30194-8.
Wu A, Ericson K, Chao W, Low WC. NFAT and AP1 are essential for the expression of a glioblastoma multiforme related IL-13Ra2 transcript. Cell Oncol. 2010;32(5–6):313–29. https://doi.org/10.3233/CLO-2010-0524.
Wu HB, Yang S, Weng HY, Chen Q, Zhao XL, Fu WJ, Niu Q, ** YF, Wang JM, Zhang X, Yao XH, Bian XW. Autophagy-induced KDR/VEGFR-2 activation promotes the formation of vasculogenic mimicry by glioma stem cells. Autophagy. 2017;13(9):1528–42. https://doi.org/10.1080/15548627.2017.1336277.
**ang T, Lin YX, Ma W, Zhang HJ, Chen KM, He GP, Zhang X, Xu M, Feng QS, Chen MY, Zeng MS, Zeng YX, Feng L. Vasculogenic mimicry formation in EBV-associated epithelial malignancies. Nat Commun. 2018;9(1):5009. https://doi.org/10.1038/s41467-018-07308-5.
Xue W, Du X, Wu H, Liu H, **e T, Tong H, Chen X, Guo Y, Zhang W. Aberrant glioblastoma neovascularization patterns and their correlation with DCE-MRI-derived parameters following temozolomide and bevacizumab treatment. Sci Rep. 2017;7(1):13894. https://doi.org/10.1038/s41598-017-14341-9.
Yang K, Wu Z, Zhang H, Zhang N, Wu W, Wang Z, Dai Z, Zhang X, Zhang L, Peng Y, Ye W, Zeng W, Liu Z, Cheng Q. Glioma targeted therapy: insight into future of molecular approaches. Mol Cancer. 2022;21(1):39. https://doi.org/10.1186/s12943-022-01513-z.
Yao X, ** Y, Liu Y, Chen K, Yoshimura T, Liu M, Gong W, Chen C, Niu Q, Guo D, Zhang X, Wang JM, Bian X. Vascular endothelial growth factor receptor 2 (VEGFR-2) plays a key role in vasculogenic mimicry formation, neovascularization and tumor initiation by Glioma stem-like cells. PLoS ONE. 2013;8(3): e57188. https://doi.org/10.1371/journal.pone.0057188.
Yin J, Ge X, Shi Z, Yu C, Lu C, Wei Y, Zeng A, Wang X, Yan W, Zhang J, You Y. Extracellular vesicles derived from hypoxic glioma stem-like cells confer temozolomide resistance on glioblastoma by delivering miR-30b-3p. Theranostics. 2021;11(4):1763–79. https://doi.org/10.7150/thno.47057.
Yu PF, Kang AR, **g LJ, Wang YM. Long non-coding RNA CACNA1G-AS1 promotes cell migration, invasion and epithelial-mesenchymal transition by HNRNPA2B1 in non-small cell lung cancer. Eur Rev Med Pharmacol Sci. 2018;22(4):993–1002. https://doi.org/10.26355/eurrev_201802_14381.
Zhao X, Wang Q, Yang S, Chen C, Li X, Liu J, Zou Z, Cai D. Quercetin inhibits angiogenesis by targeting calcineurin in the xenograft model of human breast cancer. Eur J Pharmacol. 2016;781:60–8. https://doi.org/10.1016/j.ejphar.2016.03.063.
Zhao Z, Zhang KN, Wang Q, Li G, Zeng F, Zhang Y, Wu F, Chai R, Wang Z, Zhang C, Zhang W, Bao Z, Jiang T. Chinese Glioma Genome Atlas (CGGA): A Comprehensive Resource with Functional Genomic Data from Chinese Glioma Patients. Genomics Proteomics Bioinformatics. 2021;19(1):1–12. https://doi.org/10.1016/j.gpb.2020.10.005.
Acknowledgements
Julian Heng (0000-0002-0378-7078) provided professional English-language editing of this article (Manuscript Certificate No. 2Gg3Vk5U). We would like to thank members of the laboratory for their help and technical support for this study.
Funding
This work was supported by grants from the General Project of Liaoning Province Education Department (No. JYTMS20230121 and No. JYTMS20231838), the Liaoning Province Applied Basic Research Program (No. 2022JH2/101300013), and Natural Science Foundation of Liaoning Province (No. 2021-MS-158).
Author information
Authors and Affiliations
Contributions
TM and HW conceived and designed the experiments. HW, YS, AY and TM performed the experiments and acquired the data. HW, YS, BZ and TM analyzed and interpreted the data. HW and TM wrote the manuscript. HW, YS, TM, and DZ revised the article for important intellectual content. TM and DZ approved the final version to be published. TM and XZ provided the administrative, technical, and material support.
Corresponding authors
Ethics declarations
Ethics approval and consent to participate
Animal experiments were approved by the Ethics Committee of China Medical University (Number:KT2023868 date: 26 September 2023). The experiments were conducted in consideration of the ARRIVE guidelines.
Consent for publication
Not applicable.
Competing interests
The authors declare no competing interests.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Wang, H., Shi, Y., Zhou, X. et al. HNRNPA2B1 stabilizes NFATC3 levels to potentiate its combined actions with FOSL1 to mediate vasculogenic mimicry in GBM cells. Cell Biol Toxicol 40, 44 (2024). https://doi.org/10.1007/s10565-024-09890-5
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s10565-024-09890-5